Investigational Drug Details
| Drug ID: | D593 |
| Drug Name: | GSI |
| Synonyms: | -- |
| Type: | Miscellany |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Notch inhibitor |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | Details |
| A00412 | 35093608 | Mol Cell Proteomics | Integrated liver and plasma proteomics in obese mice reveals complex metabolic regulation. | Details |
| A00670 | 35008852 | Int J Mol Sci | Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. | Details |
| A00980 | 34911556 | BMC Biol | Enhanced hepatic respiratory capacity and altered lipid metabolism support metabolic homeostasis during short-term hypoxic stress. | Details |
| A02346 | 34408183 | Sci Rep | Key features of the environment promoting liver cancer in the absence of cirrhosis. | Details |
| A02602 | 34314306 | Immunopharmacol Immunotoxicol | The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions. | Details |
| A02620 | 34307250 | Front Pediatr | Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. | Details |
| A02815 | 34231659 | Arq Gastroenterol | PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. | Details |
| A03015 | 34163108 | World J Gastroenterol | Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. | Details |
| A03339 | 34036255 | JHEP Rep | Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. | Details |
| A03470 | 33991461 | Physiol Rep | Prevention of non-alcoholic steatohepatitis by long-term exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice. | Details |
| A03763 | 33871418 | Curr Opin Clin Nutr Metab Care | Beyond weight loss in nonalcoholic fatty liver disease: the role of carbohydrate restriction. | Details |
| A03786 | 33864571 | Mol Cell Biochem | Upregulated SOCC and IP3R calcium channels and subsequent elevated cytoplasmic calcium signaling promote nonalcoholic fatty liver disease by inhibiting autophagy. | Details |
| A03830 | 33855376 | Minerva Surg | NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. | Details |
| A03865 | 33839905 | Eur J Nutr | Improving insulin sensitivity, liver steatosis and fibrosis in type 2 diabetes by a food-based digital education-assisted lifestyle intervention program: a feasibility study. | Details |
| A04770 | 33511275 | Clin Exp Hepatol | Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. | Details |
| A05843 | 33102775 | JGH Open | Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. | Details |
| A05844 | 33102766 | JGH Open | Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients. | Details |
| A06068 | 33022287 | Food Chem Toxicol | MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement. | Details |
| A07947 | 32302728 | J Hepatol | Exercise retards hepatocarcinogenesis in obese mice independently of weight control. | Details |